- Home
- EDRY vs MNOV Comparison
EDRY vs MNOV Comparison
Compare EDRY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | MNOV |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 70.4M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | EDRY | MNOV |
|---|---|---|
| Price | $68.61 | $2.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 155.0K | 63.1K |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $10.13 | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $11.21 | $1.17 |
| 52 Week High | $71.84 | $1.96 |
Technical Indicators
Market Signals| Indicator | EDRY | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 76.31 | 81.81 |
| Support Level | $17.37 | $1.28 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.21 | 0.09 |
| MACD | 0.82 | 0.05 |
| Stochastic Oscillator | 81.48 | 92.31 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.